MedTrace Logo

Helium-Hyperoxia and 6MWT Distance in COPD

NCT00394225 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2006-10-31

No results posted yet for this study

Summary

We assessed the effect of altering inspired gas on the 6MWT distance in COPD. We hypothesized that HeO2 would improve walking distance and reduce shortness of breath compared to both RA and O2, and potentially improve quality of life for COPD patients.

Conditions

Interventions

DRUG

Oxygen

DRUG

Helium

Sponsors & Collaborators

  • Nova Scotia Health Authority

    collaborator OTHER

  • University of Saskatchewan

    lead OTHER

Principal Investigators

  • Darcy D Marciniuk, MD, FRCP(C) · University of Saskatchewan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Completion
2006-05-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00394225 on ClinicalTrials.gov